Praxis precision medicines announces plans to begin ulixacaltamide phase 3 in essential tremor by year end after completing end of phase 2 meeting with fda

Phase 3 program to include one parallel group study and one randomized withdrawal study madl11 as primary endpoint single 60 mg/day dose to be tested boston, june 09, 2023 (globe newswire) -- praxis precision medicines, inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (cns) disorders characterized by neuronal excitation-inhibition imbalance, today announced the outcomes from a recent end-of-phase 2 meeting with the u. s. food and drug administration (fda) regarding plans to advance ulixacaltamide into phase 3 for essential tremor (et).
PRAX Ratings Summary
PRAX Quant Ranking